JP2010505831A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010505831A5 JP2010505831A5 JP2009531418A JP2009531418A JP2010505831A5 JP 2010505831 A5 JP2010505831 A5 JP 2010505831A5 JP 2009531418 A JP2009531418 A JP 2009531418A JP 2009531418 A JP2009531418 A JP 2009531418A JP 2010505831 A5 JP2010505831 A5 JP 2010505831A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- amino acid
- pharmaceutical composition
- amino acids
- capsid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 88
- 150000001413 amino acids Chemical class 0.000 claims description 68
- 241000124008 Mammalia Species 0.000 claims description 36
- 241000700605 Viruses Species 0.000 claims description 32
- 210000000234 capsid Anatomy 0.000 claims description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 22
- 230000001225 therapeutic effect Effects 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 16
- 102000036639 antigens Human genes 0.000 claims description 16
- 108091007433 antigens Proteins 0.000 claims description 16
- 241001430294 unidentified retrovirus Species 0.000 claims description 12
- 230000000840 anti-viral effect Effects 0.000 claims description 8
- 241000713666 Lentivirus Species 0.000 claims description 6
- 150000001336 alkenes Chemical group 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000010076 replication Effects 0.000 claims description 5
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 108010038807 Oligopeptides Proteins 0.000 claims description 4
- 102000015636 Oligopeptides Human genes 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 150000002894 organic compounds Chemical class 0.000 claims description 4
- 230000002285 radioactive effect Effects 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 108090000371 Esterases Proteins 0.000 claims description 2
- 101100533890 Hypocrea jecorina (strain QM6a) sor3 gene Proteins 0.000 claims description 2
- 101100533874 Hypocrea jecorina (strain QM6a) sor5 gene Proteins 0.000 claims description 2
- 238000005865 alkene metathesis reaction Methods 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000003754 fetus Anatomy 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 238000005304 joining Methods 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 9
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84955106P | 2006-10-05 | 2006-10-05 | |
| PCT/US2007/021156 WO2008045238A2 (en) | 2006-10-05 | 2007-10-02 | Stabilized therapeutic small helical antiviral peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010505831A JP2010505831A (ja) | 2010-02-25 |
| JP2010505831A5 true JP2010505831A5 (OSRAM) | 2011-07-14 |
Family
ID=39283347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009531418A Pending JP2010505831A (ja) | 2006-10-05 | 2007-10-02 | 安定化した、治療用の小型のヘリックス性抗ウイルスペプチド |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8940864B2 (OSRAM) |
| EP (2) | EP2073829B1 (OSRAM) |
| JP (1) | JP2010505831A (OSRAM) |
| AU (1) | AU2007307254A1 (OSRAM) |
| CA (1) | CA2665186A1 (OSRAM) |
| ES (1) | ES2387827T3 (OSRAM) |
| WO (1) | WO2008045238A2 (OSRAM) |
| ZA (1) | ZA200901248B (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8937154B2 (en) * | 2006-10-05 | 2015-01-20 | New York Blood Center, Inc. | Stabilized therapeutic small helical antiviral peptides |
| PL2118123T3 (pl) | 2007-01-31 | 2016-06-30 | Dana Farber Cancer Inst Inc | Stabilizowane peptydy p53 i ich zastosowania |
| KR101525754B1 (ko) | 2007-03-28 | 2015-06-09 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 스티칭된 폴리펩티드 |
| JP2011522796A (ja) * | 2008-05-06 | 2011-08-04 | ニューヨーク ブラッド センター， インコーポレイテッド | 抗ウイルス細胞透過性ペプチド |
| BRPI0918833A2 (pt) * | 2008-09-22 | 2015-12-08 | Aileron Therapeutics Inc | macrociclos peptidomiméticos |
| EP2376100B1 (en) | 2009-01-14 | 2017-10-25 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| CA2807685C (en) | 2010-08-13 | 2020-10-06 | Aileron Therapeutics, Inc. | P53 derived peptidomimetic macrocycle |
| TW201806968A (zh) | 2011-10-18 | 2018-03-01 | 艾利倫治療公司 | 擬肽巨環化合物 |
| BR112014020103A2 (pt) | 2012-02-15 | 2018-10-09 | Aileron Therapeutics, Inc. | macrociclos peptidomiméticos |
| CA2864120A1 (en) | 2012-02-15 | 2013-08-22 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| KR20150082307A (ko) | 2012-11-01 | 2015-07-15 | 에일러론 테라퓨틱스 인코포레이티드 | 이치환 아미노산 및 이의 제조 및 사용 방법 |
| US9622483B2 (en) | 2014-02-19 | 2017-04-18 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| US11039621B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| US11039620B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| SG10201902598VA (en) | 2014-09-24 | 2019-04-29 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and formulations thereof |
| MX2017003797A (es) | 2014-09-24 | 2017-06-15 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos y usos de los mismos. |
| WO2016085280A1 (ko) * | 2014-11-28 | 2016-06-02 | 서울대학교산학협력단 | 세포 투과성 스테이플 펩타이드, 이의 제조방법 및 그 용도 |
| US10253067B2 (en) | 2015-03-20 | 2019-04-09 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| WO2017004548A1 (en) | 2015-07-01 | 2017-01-05 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| WO2017018595A1 (ko) * | 2015-07-28 | 2017-02-02 | 동국대학교 산학협력단 | 이중 스테이플화된 펩타이드 및 이의 용도 |
| CN108368161A (zh) | 2015-09-10 | 2018-08-03 | 艾瑞朗医疗公司 | 作为mcl-1调节剂的拟肽大环化合物 |
| WO2019133179A2 (en) * | 2017-12-01 | 2019-07-04 | Massachusetts Institute Of Technology | Solution-phase affinity selection of inhibitors from combinatorial peptide libraries |
| US20200102356A1 (en) * | 2018-10-01 | 2020-04-02 | NMC Inc. | Compositions and Methods for the Treatment of Huanglongbing (HLB) aka Citrus Greening in Citrus Plants |
| WO2022036049A2 (en) * | 2020-08-12 | 2022-02-17 | New York Blood Center, Inc. | Antiviral stapled peptides against sars-cov-2 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6187548B1 (en) * | 1993-05-23 | 2001-02-13 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Methods using human calcium sensor protein, fragments thereof and DNA encoding same |
| US6239270B1 (en) * | 1993-05-24 | 2001-05-29 | Rhone-Poulenc Rorer S.A. | Nucleic acids encoding human calcium sensor protein |
| EP2281834B1 (en) * | 1999-04-09 | 2015-03-04 | Zoetis P&U LLC | Attenuated Pasteurellaceae bacterium having a mutation in a virulence gene |
| US6790950B2 (en) * | 1999-04-09 | 2004-09-14 | Pharmacia & Upjohn Company | Anti-bacterial vaccine compositions |
| US7192713B1 (en) | 1999-05-18 | 2007-03-20 | President And Fellows Of Harvard College | Stabilized compounds having secondary structure motifs |
| US6653102B2 (en) * | 2000-10-17 | 2003-11-25 | Myriad Genetics, Inc. | Nucleic acid encoding a phosphatase 2C that interacts with Fe 65 |
| DK2332968T3 (en) | 2003-11-05 | 2016-08-22 | Dana Farber Cancer Inst Inc | Alpha-helix peptides suitable for activating or inhibiting cell death |
| WO2008009000A2 (en) * | 2006-07-13 | 2008-01-17 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in signaling pathways |
| WO2008008998A2 (en) * | 2006-07-13 | 2008-01-17 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in signaling pathways |
| CA2663188A1 (en) * | 2006-09-11 | 2008-03-20 | The Board Of Trustees Of The University Of Illinois | Modifications of cupredoxin derived peptides and methods of use thereof |
| PL2118123T3 (pl) | 2007-01-31 | 2016-06-30 | Dana Farber Cancer Inst Inc | Stabilizowane peptydy p53 i ich zastosowania |
| JP5078401B2 (ja) * | 2007-03-27 | 2012-11-21 | 株式会社Ａｄｅｋａ | 防水シート |
| US8921323B2 (en) | 2007-09-26 | 2014-12-30 | Dana Farber Cancer Institute, Inc. | Methods and compositions for modulating BCL-2 family polypeptides |
| CA2713089C (en) | 2008-01-23 | 2017-11-21 | Dana Farber Cancer Institute | Compositions and methods for the treatment of viral infections |
| JP2011522796A (ja) * | 2008-05-06 | 2011-08-04 | ニューヨーク ブラッド センター， インコーポレイテッド | 抗ウイルス細胞透過性ペプチド |
| JP6049260B2 (ja) | 2008-10-10 | 2016-12-21 | ダナ ファーバー キャンサー インスティテュート インコーポレイテッド | プロアポトーシスｂａｘ及びｂｃｌ−２ポリペプチドの化学モジュレータ |
-
2007
- 2007-10-02 EP EP07839140A patent/EP2073829B1/en not_active Not-in-force
- 2007-10-02 AU AU2007307254A patent/AU2007307254A1/en not_active Abandoned
- 2007-10-02 ES ES07839140T patent/ES2387827T3/es active Active
- 2007-10-02 EP EP20120169140 patent/EP2517720A1/en not_active Ceased
- 2007-10-02 US US12/438,414 patent/US8940864B2/en active Active
- 2007-10-02 JP JP2009531418A patent/JP2010505831A/ja active Pending
- 2007-10-02 WO PCT/US2007/021156 patent/WO2008045238A2/en not_active Ceased
- 2007-10-02 CA CA002665186A patent/CA2665186A1/en not_active Abandoned
-
2009
- 2009-02-20 ZA ZA200901248A patent/ZA200901248B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010505831A5 (OSRAM) | ||
| JP7362142B2 (ja) | 環状ｎｔｃｐ標的化ペプチドおよび侵入阻害剤としてのその使用 | |
| JP2010510236A5 (OSRAM) | ||
| Berkhout et al. | Is there a future for antiviral fusion inhibitors? | |
| RU2008126305A (ru) | Новый пептид | |
| JP2012521201A5 (OSRAM) | ||
| JP2006020648A5 (OSRAM) | ||
| JP2011006428A5 (OSRAM) | ||
| JP2008508859A5 (OSRAM) | ||
| KR102599942B1 (ko) | Hbv 및 hdv 감염의 조합 치료법 | |
| JP2010500399A5 (OSRAM) | ||
| JP2008530245A5 (OSRAM) | ||
| JP2011530599A5 (OSRAM) | ||
| JP2014111628A (ja) | ウイルス融合のインヒビターのコレステロール誘導体 | |
| JP2012504602A5 (OSRAM) | ||
| RU2014111179A (ru) | КОНЪЮГАТЫ ИНТЕРФЕРОНА λ1 И ПОЛИЭТИЛЕНГЛИКОЛЯ | |
| JP2014525939A5 (OSRAM) | ||
| Niyomnaitham et al. | Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants | |
| JP2009510134A5 (OSRAM) | ||
| WO2007137591A8 (en) | Hiv vaccine | |
| JP2010511706A5 (OSRAM) | ||
| JP6910043B2 (ja) | ヘマグルチニン結合ペプチド、および、これを含むインフルエンザウイルス感染症の予防・治療薬 | |
| CN118615306A (zh) | 一种抑制病毒感染的药物组合物及其应用 | |
| WO2023196913A2 (en) | Methods of treating ankylosing spondylitis | |
| AU1906592A (en) | Peptides for use in induction of t cell activation against hiv-1 |